 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | exeporfinium chloride (XF-73) / Destiny Pharma
Journal: Screening of the novel antimicrobial drug, XF-73, against 2,527 Staphylococcus species clinical isolates. (Pubmed Central) - Oct 30, 2023
This dataset expands the knowledge of the breadth of activity of this novel antibacterial against a wide range of global S. aureus isolates and supports the potential utility of XF-73 for the treatment of patients who are S. aureus nasal carriers. Similar results were also obtained for multidrug-resistant isolates of other Staphylococcus species included in the study and collectively support the continued clinical development of XF-73 as an effective anti-staphylococcal drug.
- | exeporfinium chloride (XF-73) / Destiny Pharma, XF-70 / Destiny Pharma
Journal: Antimicrobial effects of XF drugs against Candida albicans and its biofilms. (Pubmed Central) - Sep 25, 2023
Overall, the results highlight the potential of XF drugs as new drugs for the management of topical infections caused by C. albicans. Further studies are warranted on the development of XF drugs as antifungals, particularly for XF-73 and XF-70.
- | exeporfinium chloride (XF-73) / Destiny Pharma
Preclinical, Journal: Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection Models. (Pubmed Central) - Jul 31, 2023
SEM analysis demonstrated that this cell wall and cell membrane disruption did not lead to disintegration of the plasma membrane, and did not cause bacterial cell lysis. Therefore, XF-73 may be an effective drug alternative to combat multi-drug-resistant skin infections in the clinical setting.
- || exeporfinium chloride (XF-73) / Destiny Pharma
P2 data, Journal, Surgery: Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to surgery significantly reduced Staphylococcus aureus nasal carriage in cardiac surgery patients: Safety and efficacy results from a randomized placebo-controlled phase 2 study. (Pubmed Central) - Mar 25, 2023
We studied 83 cardiac-surgery patients with nasal S. aureus carriage who received 4 intranasal administrations of XF-73 nasal gel or placebo <24 hours before surgery. One hour before surgery, patients exhibited a S. aureus nasal carriage reduction of 2.5 log with XF-73 compared to 0.4 log CFU/mL for those who received placebo (95% CI, -2.7 to -1.5; P < .0001).
- | Invanz (ertapenem) / Merck (MSD), exeporfinium chloride (XF-73) / Destiny Pharma, XF-70 / Destiny Pharma
Journal: Antibacterial and Antibiofilm Potency of XF Drugs, Impact of Photodynamic Activation and Synergy With Antibiotics. (Pubmed Central) - Jul 20, 2022
XF drugs exhibited significant antimicrobial activity against Gram-positive bacteria, with PD enhancement of bacterial susceptibility. Additionally, XF drugs displayed synergy with conventional antibiotics and demonstrated antibiofilm effects.
- exeporfinium chloride (XF-73) / Destiny Pharma
Destiny Pharma plc (Theater 4) - Jun 4, 2022 - Abstract #BIO2022BIO_272;
It has two late-stage clinical assets which it is preparing for Phase 3 studies - NTCD-M3 for prevention of recurrence of C. difficile infection; and XF-73 for prevention of post-surgical S. aureus infections...Beyond this, it has a pipeline related to its proprietary and patent protected XF platform; and separately a preclinical stage collaboration focused on COVID-19. Destiny is also open to collaborations involving its earlier programmes and expanding its pipeline of microbiome assets.
- exeporfinium chloride (XF-73) / Destiny Pharma
Antibacterial efficacy of XF-73 via two mechanisms of action against Gram-positive microorganisms in biofilm mode of growth () - May 2, 2022 - Abstract #ECCMID2022ECCMID_4778;
- ||| mupirocin / Generic mfg., exeporfinium chloride (XF-73) / Destiny Pharma
P4 data: Our client @DestinyPharma has noted a Phase 4 study presented during @IDWeek2021 which provides strong support for the potential of their XF-73 nasal product as an alternative to mupirocin. #AMR #biotech #IDWeek2021 #DEST #microbiome (Twitter) - Oct 18, 2021
- | exeporfinium chloride (XF-73) / Destiny Pharma
Clinical, P1 data, Journal: A two-part phase I study to establish and compare the safety and local tolerability of two nasal formulations of XF-73 for decolonization of Staphylococcus aureus: A previously investigated 0.5 mg/g viscosified gel formulation versus a modified formulation. (Pubmed Central) - Jun 24, 2021
XF-73 was found to be safe and was tolerated with minimal side effects at doses of 0.5 mg/g 2% gel and 2 mg/g 2% gel in healthy volunteers. These findings support moving on to Phase 2 trials to further evaluate the efficacy of XF-73.
- exeporfinium chloride (XF-73) / Destiny Pharma
[VIRTUAL] Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients: preliminary results from a phase II study () - Jun 20, 2021 - Abstract #ECCMID2021ECCMID_4445;
- | exeporfinium chloride (XF-73) / Destiny Pharma
Journal: Assessing the Potential for Staphylococcus aureus to Evolve Resistance to XF-73. (Pubmed Central) - May 26, 2021
These findings support moving on to Phase 2 trials to further evaluate the efficacy of XF-73. No abstract available
- exeporfinium chloride (XF-73) / Destiny Pharma
[VIRTUAL] Antimicrobial efficacy of XF-73 and antibiotic comparators against clinically relevant Gram-positive microorganisms in biofilm mode of growth () - May 20, 2021 - Abstract #ECCMID2021ECCMID_3544;
- ||| exeporfinium chloride (XF-73) / Destiny Pharma
Trial completion: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (clinicaltrials.gov) - Apr 5, 2021
P2, N=124, Completed, Sponsor: Destiny Pharma Plc
No abstract available Active, not recruiting --> Completed
- || exeporfinium chloride (XF-73) / Destiny Pharma
Enrollment closed: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (clinicaltrials.gov) - Jan 8, 2021
P2, N=125, Active, not recruiting, Sponsor: Destiny Pharma Plc
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| exeporfinium chloride (XF-73) / Destiny Pharma
Enrollment change: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (clinicaltrials.gov) - Nov 12, 2020
P2, N=125, Recruiting, Sponsor: Destiny Pharma Plc
Recruiting --> Active, not recruiting N=200 --> 125
- || exeporfinium chloride (XF-73) / Destiny Pharma
Trial completion date, Trial primary completion date: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (clinicaltrials.gov) - Apr 16, 2020
P2, N=200, Recruiting, Sponsor: Destiny Pharma Plc
N=200 --> 125 Trial completion date: Jul 2020 --> Mar 2021 | Trial primary completion date: Apr 2020 --> Dec 2020
- | rifampicin / Generic mfg.
Journal: Staphylococcus aureus nasal decolonization strategies: a review. (Pubmed Central) - Mar 14, 2020
Some of them are still in preclinical phases, and others have reached clinical trials, but further research is needed. Special interest should be given to single dose decolonization strategies and to molecules that do not select resistant strains.
- Spread of clonal linezolid-resistant Staphylococcus epidermidis in an intensive care unit associated with linezolid exposure () - Feb 4, 2020 - Abstract #ECCMID2020ECCMID_2598;
We report herein that previous exposure to LNZ substantially increased the risk of LNZ-resistant S. epidermidis infection even in the case of clonal spread of LNZ-resistant isolates. These findings highlight the need for reducing the use of LNZ as a critical way to preserve their efficacy in the future.
- || exeporfinium chloride (XF-73) / Destiny Pharma
Trial completion date, Trial primary completion date: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (clinicaltrials.gov) - Dec 17, 2019
P2, N=200, Recruiting, Sponsor: Destiny Pharma Plc
These findings highlight the need for reducing the use of LNZ as a critical way to preserve their efficacy in the future. Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Nov 2019 --> Apr 2020
- ||| exeporfinium chloride (XF-73) / Destiny Pharma
Enrollment open: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (clinicaltrials.gov) - Jun 13, 2019
P2, N=200, Recruiting, Sponsor: Destiny Pharma Plc
Trial completion date: Dec 2019 --> Jul 2020 | Trial primary completion date: Nov 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- |||| exeporfinium chloride (XF-73) / Destiny Pharma
New P2 trial: Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (clinicaltrials.gov) - Apr 16, 2019
P2, N=200, Not yet recruiting, Sponsor: Destiny Pharma Plc
- exeporfinium chloride (XF-73) / Destiny Pharma
Trial completion, Trial primary completion date: Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 (clinicaltrials.gov) - Apr 8, 2016
P1, N=48, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: May 2015 --> Aug 2015
- exeporfinium chloride (XF-73) / Destiny Pharma
Trial completion: Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects (clinicaltrials.gov) - Feb 19, 2015
P1/2, N=60, Completed, Sponsor: Destiny Pharma Ltd
Recruiting --> Completed | Trial primary completion date: May 2015 --> Aug 2015 Recruiting --> Completed
- | exeporfinium chloride (XF-73) / Destiny Pharma
New P1/2 trial: Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects (clinicaltrials.gov) - Nov 4, 2014
P1/2, N=60, Recruiting, Sponsor: Destiny Pharma Ltd
- exeporfinium chloride (XF-73) / Destiny Pharma
Trial primary completion date: Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 (clinicaltrials.gov) - Sep 12, 2014
P1, N=56, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Trial primary completion date: May 2014 --> May 2015
- exeporfinium chloride (XF-73) / Destiny Pharma
Enrollment open: Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 (clinicaltrials.gov) - Aug 29, 2012
P1, N=56, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: May 2014 --> May 2015 Not yet recruiting --> Recruiting
- exeporfinium chloride (XF-73) / Destiny Pharma
New P1 trial: Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 (clinicaltrials.gov) - May 3, 2012
P1, N=56, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)